PTSD

Currently, the only medications approved by the FDA for PTSD are the selective serotonin reuptake inhibitors (SSRIs) sertraline and paroxetine. However, these medications don’t work for everyone.

Women are more than twice as likely to develop post-traumatic stress disorder than men, and a new study demonstrates for the first time that women have a greater inherited biological risk.

There’s a dearth of research on older veterans with PTSD in long-term care settings. A new study sought to determine who they are.

A systematic review and network meta-analysis examined research on four types of treatment for children with post-traumatic stress disorder. Trauma-focused cognitive behavioral therapy was the clear winner.

During the COVID-19 pandemic, healthcare workers faced several mental health challenges, experiencing repeated exposure to life-threatening situations that increased their risk of PTSD and other trauma-related conditions.

After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.

In June, an FDA advisory committee voted against approval of midomafetamine capsules (MDMA) for adults living with posttraumatic stress disorder (PTSD).

Patients with PTSD in the clinical trials of midomafetamine were able to guess whether they received treatment or placebo. Regulators and advisory committee members said this could have impacted efficacy results. FDA’s decision is expected by Aug. 11, 2024.

If approved, midomafetamine would be the first psychedelic-assisted therapy approved for any mental health condition. The advisory committee meeting is June 4, 2024.